Also, within the ELN2022 intermediate risk group, there were no significant outcome differences between AML patients with a high or low FLT3-ITD allelic ratio (0.5 cut-off), t(9;11), or other ELN2022 intermediate risk aberrations (Fig. 3B and Supplementary Fig. S6C, D). This evidence concerns the gene FLT3 and acute myeloid leukemia.